Related Experiment Video

Updated: May 9, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target

Benjamin D Ferguson1, Ren Liu, Cleo E Rolle

  • 1Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA.

Plos One
|July 12, 2013
PubMed

Insights

EphB4 receptor tyrosine kinase is overexpressed in lung cancer, promoting tumor growth. Inhibiting EphB4 halts tumor growth alone and regresses tumors with paclitaxel, suggesting it as a novel therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Lung cancer patient survival remains a challenge despite advancements in treatment.
  • Receptor tyrosine kinases are key in lung cancer pathogenesis, with some kinase inhibitors showing clinical efficacy.
  • EphB4 receptor tyrosine kinase is a potential target in various cancers.

Purpose of the Study:

  • To systematically investigate the role of EphB4 in lung cancer.
  • To evaluate EphB4 as a potential therapeutic target for lung cancer.

Main Methods:

  • Quantitative analysis of EphB4 expression in lung tumors versus normal tissues.
  • Assessment of EphB4 gene copy number alterations.
  • In vitro studies on cellular proliferation, colony formation, and motility.
  • In vivo studies using mouse xenograft models with EphB4 inhibition (single-agent and combination therapy).

Main Results:

  • EphB4 is overexpressed (3-fold) in lung tumors compared to normal tissues, with frequent gene copy number increases.
  • EphB4 overexpression enhances cellular proliferation, colony formation, and motility.
  • EphB4 inhibition reduces cancer cell viability in vitro.
  • EphB4 inhibition halts tumor growth in vivo as a single-target strategy.
  • Combination therapy with EphB4 inhibition and paclitaxel leads to near-complete tumor regression.

Conclusions:

  • EphB4 plays a significant role in lung cancer development and progression.
  • EphB4 represents a promising novel therapeutic target for lung cancer.
  • Clinical trials for anti-EphB4 therapies, including combination strategies, are warranted.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...